loading...| Preferred Name |
pasireotide |
|
| Synonyms |
SOM230 |
|
| Definitions |
A synthetic long-acting cyclic peptide with somatostatin-like activity. Pasireotide activates a broad spectrum of somatostatin receptors, exhibiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2.This agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C69131" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C69131" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000540440 |
|
| altLabel |
SOM230 |
|
| cui |
C1136845 C1872203 |
|
| DATE FIRST PUBLISHED |
2007-04-02 |
|
| Date last modified |
2010-05-20 |
|
| definition |
A synthetic long-acting cyclic peptide with somatostatin-like activity. Pasireotide activates a broad spectrum of somatostatin receptors, exhibiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2.This agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C69131" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C69131" NCI Thesaurus) |
|
| NCI ID |
C69131 |
|
| notation |
CDR0000540440 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
pasireotide |
|
| tui |
T109 T116 T121 |